Cerebrospinal fluid and urinary biomarkers in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 128, Issue 5, 2013, Pages 321-327

  Dobson, R ^a   Topping, J ^a   Davis, A ^a   Thompson, E ^b   Giovannoni, G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CSF; Free light chain; Neopterin; Oligoclonal bands; Ubiquitin C terminal hydrolase L1; Urine

Indexed keywords

CREATININE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; NEOPTERIN; UBIQUITIN THIOLESTERASE;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ACTIVATION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; HUMAN; IMMUNE SYSTEM; MALE; MULTIPLE SCLEROSIS; PLASMA CELL; URINALYSIS;

CSF; FREE LIGHT CHAIN; NEOPTERIN; OLIGOCLONAL BANDS; UBIQUITIN C-TERMINAL HYDROLASE-L1; URINE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEOPTERIN; OLIGOCLONAL BANDS; STATISTICS AS TOPIC; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84885427253     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12119     Document Type: Article

References (35)

1. Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999;122(Pt 1):141-59.
2. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Multiple Sclerosis 2002;8:359-65.
3. Schaffler N, Kopke S, Winkler L et al. Accuracy of diagnostic tests in multiple sclerosis - a systematic review. Acta Neurol Scand 2011;124:151-64.
4. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127(Pt 7):1463-78.
5. Freedman MS, Thompson EJ, Deisenhammer F et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865-70.
6. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
7. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2010;219:1-7.
8. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012;18:552-6.
9. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 2011;305:1-10.
10. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet neurology 2002;1:232-41.
11. Giovannoni G, Thompson EJ. Urinary markers of disease activity in multiple sclerosis. Mult Scler 1998;4:247-53.
12. Pezzoli A, Pascali E. Bence Jones proteinuria in multiple sclerosis. Clin Chem 1987;33:1923-4.
13. Mehta P, Cook S, Troiano R, Coyle P. Increased free light chains in the urine from patients with multiple sclerosis. Neurology 1991;41:540-4.
14. Dobson R, Miller R, Palmer H et al. Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. J Neuroimmunol. 2010;220:99-103.
15. Arneth B, Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009;119:39-44.
16. Rudick R, Peter D, Bidlack J, Knutson D. Multiple sclerosis: free light chains in cerebrospinal fluid. Neurology 1985;35(10):1443-9.
17. Jn R, Trinkaus K, Cross A. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006;67:1288-90.
18. Huber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-6.
19. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res 1990;50(10):2863-7.
20. Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand 1987;75:352-5.
21. Ott M, Demisch L, Engelhardt W, Fischer PA. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J Neurol 1993;241:108-14.
22. Shaw CE, Dunbar PR, Macaulay HA, Neale TJ. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 1995;242:53-8.
23. Giovannoni G, Lai M, Kidd D et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain. 1997;120 (Pt 1):1-13.
24. Khorami H, Neyestani T, Kadkhodaee M, Lotfi J. Increased urinary neopterin: creatinine ratio as a marker of activation of cell-mediated immunity and oxidative stress in the Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol 2003;2:155-8.
25. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res 1998;18:967-75.
26. Bagnato F, Pozzilli C, Scagnolari C et al. A one-year study on the pharmacodynamic profile of interferon-beta1a in MS. Neurology 2002;58:1409-11.
27. Cook SD, Quinless JR, Jotkowitz A, Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001;57:1080-4.
28. Nomoto M, Utatsu Y, Soejima Y, Osame M. Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis. Neurology 1991;41:457.
29. Lewis SB, Wolper R, Chi YY et al. Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J Neurosci Res 2010;88:1475-84.
30. Brophy GM, Mondello S, Papa L et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 2011;28:861-70.
31. Papa L, Akinyi L, Liu MC et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 2010;38:138-44.
32. Dobson R, Meier UC, Giovannoni G. More to come: humoral immune responses in MS. J Neuroimmunol 2011;240-241:13-21.
33. Bartosik-Psujek H, Psujek M, Jaworski J, Stelmasiak Z. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand 2011;123:252-6.
34. Dhungana S, Sharrack B, Woodroofe N. Cytokines and chemokines in idiopathic intracranial hypertension. Headache 2009;49:282-5.
35. Zhang HL, Zhang XM, Mao XJ et al. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurol Scand 2012;125:129-35.